Abstract Number: 1093 • ACR Convergence 2023
Development of Adaptive Immunity Against Different SARS-CoV-2 Variants over the Course of Three COVID-19 Vaccinations in Patients with Inflammatory Rheumatic Diseases
Background/Purpose: Even though individuals with inflammatory rheumatic diseases (IRDs) were excluded from the SARS-CoV-2 vaccine trails, studies have shown that these individuals at risk of…Abstract Number: 1677 • ACR Convergence 2023
Two-week Break in Methotrexate Treatment and COVID-19 Vaccine Response. Results of the Vaccine Response on off Methotrexate (VROOM) Study, an Open Label, Prospective, Two-arm Parallel-group, Multi-center, Superiority, Randomized Controlled Trial
Background/Purpose: Immunosuppressive treatments inhibit vaccine-induced immunity. We evaluated if a two-week interruption of methotrexate treatment immediately after COVID-19 booster improved antibody response against spike protein…Abstract Number: 1935 • ACR Convergence 2023
Pre-exposure Prophylaxis with Tixegvimab/cilgavimab Is Effective in Limiting the Risk and Severity of COVID-19 in Patients with Auto Immune or Inflammatory Diseases at Increased Risk of Severe COVID-19
Background/Purpose: Patients with autoimmune or inflammatory diseases treated with immunosuppressants such as anti-CD20 are at increased risk for severe COVID-19 and have a high probability…Abstract Number: 2536 • ACR Convergence 2023
DMARD Adherence During the COVID-19 Pandemic and Association with Risk of COVID-19 Infection
Background/Purpose: The COVID-19 pandemic affected medication adherence in patients with autoimmune disease (AD) due to their fear of contracting COVID-19, financial hardship, and medication shortage.…Abstract Number: 0202 • ACR Convergence 2023
Analysis of the Effects of Immunosuppressive Therapy on Herpes Zoster Events After Each of Three Doses of the BNT162b2 mRNA Vaccine in Patients with Spondyloarthritis (SpA)
Background/Purpose: The importance and efficacy of mRNA COVID-19 vaccination in coping with the pandemic are well established, but inconsistencies remain in the data regarding side…Abstract Number: 0224 • ACR Convergence 2023
Risk Factors and Outcomes for Repeat COVID-19 Infection Among Patients with Systemic Autoimmune Rheumatic Diseases: A Case-control Study
Background/Purpose: As initial COVID-19 infections become nearly ubiquitous and the available prevention and treatment strategies evolve, patients with systemic autoimmune rheumatic diseases (SARDs) may be…Abstract Number: 1141 • ACR Convergence 2023
COVID-19 Vaccination Status and Adverse Events Following SARS-CoV-2 Vaccine in Autoimmune Inflammatory Rheumatic Disease (AIRD) Patients: A Single Center Experience
Background/Purpose: Autoimmune inflammatory rheumatic diseases (AIRD) were associated with an increased risk for COVID-19 infection, worse clinical outcomes, and COVID-19- related deaths. Vaccines carry the…Abstract Number: 1754 • ACR Convergence 2023
Novel and Unique Rheumatoid Factors Cross-React with Viral Epitopes in COVID-19
Background/Purpose: Rheumatoid factors (RFs), polyreactive antibodies canonically known to bind two conformational epitopes of IgG, are a hallmark of rheumatoid arthritis but also can arise…Abstract Number: 2036 • ACR Convergence 2023
Switch or Stay the Same? Preferences of People with Autoimmune Disease on Rituximab for Different Types of COVID-19 Vaccine Boosters
Background/Purpose: COVID-19 vaccines are now being offered as regular boosters every 6-12 months for people with autoimmune rheumatic diseases, particularly for people on rituximab, where…Abstract Number: 2564 • ACR Convergence 2023
The Effectiveness of a Fourth Dose of COVID-19 mRNA Vaccine in Patients with Systemic Autoimmune Rheumatic Diseases Using Immunomodulators: An Emulated Target Trial
Background/Purpose: Many patients with systemic autoimmune rheumatic diseases (SARDs) using immunomodulators have blunted humoral responses to COVID-19 vaccines. As such, the initial mRNA vaccine series…Abstract Number: 0209 • ACR Convergence 2023
Safety of Bivalent SARS-CoV-2 Vaccines as a Second Booster Dose in Arthritis Patients on Immunosuppressive Therapies
Background/Purpose: Safety and efficacy of updated bivalent vaccines, containing both the original vaccine variant of SARS-CoV-2 Spike and either Omicron variants BA.1 or BA.4/5, are…Abstract Number: 0225 • ACR Convergence 2023
Breakthrough SARS-Cov-2 Infection and Disease Flares in Patients with Rheumatoid Arthritis: Result from COVAD E-Survey Study
Background/Purpose: Existing studies have shown that disease activity of patients with rheumatoid arthritis (RA) may surge after COVID-19 infection. However, factors associated with disease flares…Abstract Number: 1158 • ACR Convergence 2023
Dermatomyositis Flares After COVID-19 Vaccination and/or SARS-CoV-2 Infection
Background/Purpose: Dermatomyositis (DM) is an autoimmune disorder part of the group of idiopathic inflammatory myopathies. It is characterized by proximal muscle weakness and skin involvement.…Abstract Number: 1772 • ACR Convergence 2023
Rheumatoid Arthritis-Specific Rheumatoid Factors Develop in Some COVID-19 Patients
Background/Purpose: Rheumatoid factors (RFs), antibodies canonically known to bind two conformational epitopes of IgG Fc, are a hallmark of rheumatoid arthritis (RA) but also can…Abstract Number: 2038 • ACR Convergence 2023
Impact of COVID-19 Pandemic on Preventative Health Screenings in Rheumatology Outpatients
Background/Purpose: The COVID-19 pandemic created significant barriers to accessing recommended preventative health screening. Patients already managing a chronic disease, particularly those using immunosuppressive medications, may…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 38
- Next Page »